Skip to main content
CRONCronos Group Inc. Common ShareSell5.6·$2.75+0.14%
SellModerate Confidence
Investment thesis

Cronos Group shows genuine 40% YoY revenue growth, a strong Piotroski F-Score, and bullish above-200-day-MA technicals, but a quality score below the engine's minimum floor and a deeply negative asymmetry ratio drive an explicit exit recommendation.

Thesis pillars

  • Revenue Growth LeadershipStable
  • Piotroski Quality SignalStable
  • Negative Asymmetry Target ReachedStable
  • +2 more pillars — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Cronos Group Inc. Common Share (CRON) Stock Analysis

Breakout setup

SellGrowthQualityModerate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Sell if holding. Engine safety override at $2.75: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: Elevated put/call ratio: 2.14; Below-average business quality.

Cronos Group is a cannabinoid company selling cannabis products under the Spinach, PEACE NATURALS, LIT, and Lord Jones brands, with licensed cultivation and processing in Ontario, Canada and Israel. Two customers — Ontario Cannabis Retail Corporation and Alberta Gaming, Liquor... Read more

QualityF-score8 / 9FCF yield-1.50%
Stop $2.57Target $2.88(resistance)A.R:R -3.4:1
Analyst target$2.50-9.0%1 analysts
Range unavailable (1 analysts)

Sell if holding. Engine safety override at $2.75: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: Elevated put/call ratio: 2.14; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Score 5.6/10, moderate confidence.

Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 29d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.

10-K grounded · weekly refresh

About Cronos Group Inc. Common Share

About Cronos Group Inc. Common Share

Cronos Group sells cannabis products under the Spinach, PEACE NATURALS, LIT, and Lord Jones brands from a single reporting segment spanning licensed production in Canada and Israel. Two customers, Ontario Cannabis Retail Corporation and Alberta Gaming, Liquor and Cannabis Commission, accounted for approximately 27% and 16% of consolidated net revenues in 2025, and Cronos sold $122.4 million of product to Canadian cannabis control authorities during the year.

Cronos cultivates and processes cannabis at the Peace Naturals Campus in Ontario and through Cronos GrowCo, a 50%-owned joint venture over whose board Cronos gained majority control in July 2024 and which the company describes as its principal cannabis source; Cronos holds the right, but not the obligation, to purchase up to 70% of GrowCo's total production. In Israel, Cronos Israel distributes PEACE NATURALS and LIT medical cannabis through pharmacies under IMC-GAP, IMC-GMP, and IMC-GDP certifications, and the company has expanded LIT and Lord Jones distribution into Germany and the United Kingdom through third-party partners. Altria Group beneficially owned 41.0% of Cronos common shares as of December 31, 2025 and holds board-nomination, approval, and pre-emptive rights under an investor rights agreement tied to its ownership threshold.

Show full overview

Cronos does not engage in any U.S. Schedule I cannabis activity, insulating it from federal enforcement risk that touches U.S.-domiciled operators, even after President Trump's December 18, 2025 executive order directed the Attorney General to expedite rescheduling marijuana to Schedule III — a change that would not take effect until the required federal rulemaking process concludes. Government-channel dependency is the more immediate exposure: Canadian sales flow through provincial cannabis control authorities that can renegotiate prices or terminate supply agreements at their election, concentrating Cronos's two largest customer relationships within government-run distribution monopolies rather than diversified retail accounts.

See also: Healthcare · Drug Manufacturers - Specialty & Generic

From Cronos Group Inc. Common Share's most recent 10-K filing, extracted July 6, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-07-08

Recent Developments — Cronos Group Inc. Common Share

Generated 2026-07-08T21:14:29Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Aug 6, 202629d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Target reached (-22.8% upside)
Quality below floor (2.8 < 4.0)

Key Metrics

P/E (TTM)
P/E (Fwd)-69.0
Mkt Cap$1.0B
EV/EBITDA-130457.1
Profit Mgn-1.1%
ROE0.5%
Rev Growth40.1%
Beta1.24
DividendNone
Rating analysts9

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C2.14bearish
IV120%elevated

Concentration Risks(10-K Item 1A)

  • MEDIUMCustomerOntario Cannabis Retail Corporation27%
    10-K Item 1: 'there were two major customers, Ontario Cannabis Retail Corporation and Alberta Gaming, Liquor and Cannabis Commission, which accounted for approximately 27% and 16%, respectively'
  • LOWCustomerAlberta Gaming, Liquor and Cannabis Commission16%
    10-K Item 1: 'there were two major customers, Ontario Cannabis Retail Corporation and Alberta Gaming, Liquor and Cannabis Commission, which accounted for approximately 27% and 16%, respectively'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker·1 ceiling hit

Unprofitable operations — net margin -1.1%. Quality floor flags this regardless of sector context.static

Roa
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Roe
0.2
Gross Margin
3.9
Current Ratio
5.0
Moat
7.1
Piotroski F
8.9
Cash-burning: FCF -10% of revenueStrong Piotroski F-Score: 8/9Quality concerns
GatesMomentum 4.4<4.5A.R:R -3.4=NEGATIVEInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 29d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARBreakoutSuitability: Aggressive
RSI
62 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $2.57Resistance $2.94

Price Targets

$3
$3
A.Upside+4.7%
A.R:R-3.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (-22.8% upside)
! Quality below floor (2.8 < 4.0)
! momentum at 4.4 (below the engine's 4.5 threshold)

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-08-06 (29d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CRON stock a buy right now?

Sell if holding. Engine safety override at $2.75: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: Elevated put/call ratio: 2.14; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Prior stop was $2.57. Score 5.6/10, moderate confidence.

What is the CRON stock price target?

Take-profit target: $2.88 (+4.5% upside). Prior stop was $2.57. Stop-loss: $2.57.

What are the risks of investing in CRON?

Target reached (-22.8% upside); Quality below floor (2.8 < 4.0).

Is CRON overvalued or undervalued?

Cronos Group Inc. Common Share trades at a P/E of N/A (forward -69.0). TrendMatrix value score: 5.9/10. Verdict: Sell.

What do analysts say about CRON?

9 analysts cover CRON with a consensus score of 4.1/5. Average price target: $3.

What does Cronos Group Inc. Common Share do?Cronos Group is a cannabinoid company selling cannabis products under the Spinach, PEACE NATURALS, LIT, and Lord Jones...

Cronos Group is a cannabinoid company selling cannabis products under the Spinach, PEACE NATURALS, LIT, and Lord Jones brands, with licensed cultivation and processing in Ontario, Canada and Israel. Two customers — Ontario Cannabis Retail Corporation and Alberta Gaming, Liquor and Cannabis Commission — accounted for approximately 27% and 16% of consolidated net revenues in 2025, and Altria Group holds a 41.0% equity stake with board and governance rights.

Related stocks: IRWD (Ironwood Pharmaceuticals, Inc.) · ANIP (ANI Pharmaceuticals, Inc.) · INDV (Indivior Pharmaceuticals, Inc.) · COLL (Collegium Pharmaceutical, Inc.) · SUPN (Supernus Pharmaceuticals, Inc.)
Home Stocks CRON

Latest news

Latest News

Benzinga7d ago